Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A proof-of-concept trial assessing ARGX-117 in prevention of delayed graft function and/or allograft failure after kidney transplantation

Next Previous
Trial Profile

A proof-of-concept trial assessing ARGX-117 in prevention of delayed graft function and/or allograft failure after kidney transplantation

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empasiprubart (Primary)
  • Indications Delayed graft function
  • Focus Proof of concept; Therapeutic Use
  • Sponsors argenx

Most Recent Events

  • 13 Jan 2025 According to Argenx media release, topline results expected in DGF in second half of 2025.
  • 02 Mar 2023 According to Argenx media release, this trial is expected to initiate in the second half of 2023.
  • 27 Oct 2022 According to Argenx media release, this trial is expected to initiate following regulatory discussions.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top